NEW YORK (GenomeWeb) – Belgian theranostic firm OncoDNA announced today that it has signed an agreement to provide patient-enrollment services for clinical trials of BioClin Therapeutics' investigational cancer treatment B-701.
B-701 is a monoclonal antibody being developed for treating relapsed/refractory metastatic urothelial carcinoma with FGFR3 molecular alterations.
Under the terms of the deal, OncoDNA will help BioClin identify metastatic bladder cancer patients with FGFR3 mutations for enrollment in two Phase II trials of B-701. OncoDNA said its precision enrollment services team will engage physicians across Europe to inform them about the studies and the potential for patient participation.
Additional terms were not disclosed.
"This partnership with BioClin is another important step in our strategy to provide services to research and development companies that enable precision medicine," OncoDNA CEO Jean-Pol Detiff said in a statement.
In addition to its suite of tumor profiling products that include the OncoTrace and OncoSelect liquid biopsy tests, OncoDNA offers clinical testing, patient enrollment, biospecimen analysis, and clinical data interpretation services to biopharmaceutical partners.